



Clinical trial results:

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Following First-line Systemic Anti-cancer Therapy

Summary

EudraCT number	2018-000824-32
Trial protocol	GB DK
Global end of trial date	20 November 2018

Results information

Result version number	v1 (current)
This version publication date	03 July 2020
First version publication date	03 July 2020

Trial information

Trial identification

Sponsor protocol code	V943A-003
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03520959
WHO universal trial number (UTN)	-
Other trial identifiers	IMDZ-04-1702: Immune Design Corp. Protocol Number

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 November 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 November 2018
Global end of trial reached?	Yes
Global end of trial date	20 November 2018
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 September 2018
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 1
Worldwide total number of subjects	1
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

The study was terminated early by the Sponsor.

Pre-assignment

Screening details:

Participants with synovial sarcoma expressing New York esophageal squamous cell carcinoma-1 (NY-ESO-1) were recruited in the United States.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Carer, Assessor, Subject

Arms

Arm title	CMB305
------------------	--------

Arm description:

A sequential regimen of LV305 and G305.

Arm type	Experimental
Investigational medicinal product name	LV305
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered via subcutaneous (SC) injection.

Investigational medicinal product name	G305
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Administered via intramuscular (IM) injection.

Number of subjects in period 1	CMB305
Started	1
Completed	0
Not completed	1
Study terminated by Sponsor	1

Baseline characteristics

Reporting groups

Reporting group title	CMB305
-----------------------	--------

Reporting group description:

A sequential regimen of LV305 and G305.

Reporting group values	CMB305	Total	
Number of subjects	1	1	
Age Categorical			
Units:			
Between 18 and 65 years	1	1	
Sex: Female, Male			
Data are not reported due to the risk of identification of a person.			
Units:			
Subjects	1	1	
Ethnicity			
Data are not reported due to the risk of identification of a person.			
Units: Subjects			
Subjects	1	1	
Race			
Data are not reported due to the risk of identification of a person.			
Units: Subjects			
Subjects	1	1	

End points

End points reporting groups

Reporting group title	CMB305
Reporting group description: A sequential regimen of LV305 and G305.	

Primary: Progression-Free Survival (PFS)

End point title	Progression-Free Survival (PFS) ^[1]
-----------------	--

End point description:

PFS is defined as the time from randomization to the investigator-determined date of disease progression or death, whichever comes first, using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). No data were collected or analyzed for this outcome measure due to early termination of the study.

End point type	Primary
----------------	---------

End point timeframe:

From randomization to investigator-determined date of disease progression or death, assessed up to 24 months.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The study terminated prior to data collection and analysis.

End point values	CMB305			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[2]			
Units: Months				
median (confidence interval 95%)	(to)			

Notes:

[2] - The study terminated early and no endpoint data were analyzed.

Statistical analyses

No statistical analyses for this end point

Primary: Overall Survival (OS)

End point title	Overall Survival (OS) ^[3]
-----------------	--------------------------------------

End point description:

OS is defined as the time from randomization to the date of death. No data were collected or analyzed for this outcome measure due to early termination of the study.

End point type	Primary
----------------	---------

End point timeframe:

From randomization to date of death, assessed up to 66 months.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The study terminated prior to data collection and analysis.

End point values	CMB305			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[4]			
Units: Months				
median (confidence interval 95%)	(to)			

Notes:

[4] - The study terminated early and no endpoint data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Next Treatment (TTNT)

End point title	Time to Next Treatment (TTNT)
-----------------	-------------------------------

End point description:

TTNT is defined as the time from randomization to the start of post-study treatment subsequent intervention: [TTNT = start date of subsequent intervention – randomization date + 1]. Subsequent intervention includes anticancer therapy, cancer-related surgery and local regional therapy. Participants who do not start any post-study treatment intervention will be censored at their last known date of being alive. No data were collected or analyzed for this outcome measure due to early termination of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

From last dose of CMB305 to initiation of new therapy, assessed up to 24 months.

End point values	CMB305			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[5]			
Units: Months				
median (confidence interval 95%)	(to)			

Notes:

[5] - The study terminated early and no endpoint data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Distant Metastasis Free Survival (DMFS)

End point title	Distant Metastasis Free Survival (DMFS)
-----------------	---

End point description:

DMFS is defined as the time from randomization to evidence of a new distant metastasis not documented at time of randomization: [DMFS = a new distant metastasis documented date – randomization date + 1]. Participants who do not have any new distant metastasis will be censored at their last tumor assessment. No data were collected or analyzed for this outcome measure due to early termination of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization to investigator-determined date of disease progression or death, assessed up to 24 months.

End point values	CMB305			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[6]			
Units: Months				
median (confidence interval 95%)	(to)			

Notes:

[6] - The study terminated early and no endpoint data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Response Rate (ORR)

End point title	Overall Response Rate (ORR)
-----------------	-----------------------------

End point description:

ORR defined by RECIST v1.1 will be summarized by the number and percent of subjects who achieve a complete response (CR) or partial response (PR) based on the investigator's assessment. ORR will be compared between treatment arms using a logistic regression. No data were collected or analyzed for this outcome measure due to early termination of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization to investigator-determined date of disease progression, assessed up to 24 months.

End point values	CMB305			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[7]			
Units: Percentage of participants				
number (confidence interval 95%)	(to)			

Notes:

[7] - The study terminated early and no endpoint data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE)

End point title	Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE)
-----------------	--

End point description:

Safety will be assessed primarily based on reported adverse events (AEs), medical events of interest (MEOIs), laboratory values, and concomitant medications reported from initiation of treatment with CMB305 or placebo. No data were collected or analyzed for this outcome measure due to early termination of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization to investigator-determined date of disease progression or death, assessed up to approximately 2 months.

End point values	CMB305			
Subject group type	Reporting group			
Number of subjects analysed	1 ^[8]			
Units: Participants	1			

Notes:

[8] - The study terminated early and no endpoint data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Quality of Life (QoL): EuroQol 5-Dimension 5 Level (EQ-5D-5L) and EuroQol 5-Dimension Youth (EQ-5D-Y) Questionnaires

End point title	Quality of Life (QoL): EuroQol 5-Dimension 5 Level (EQ-5D-5L) and EuroQol 5-Dimension Youth (EQ-5D-Y) Questionnaires
-----------------	--

End point description:

QoL evaluated using the EQ-5D-5L (participants ≥ 18 years of age) or the EQ-5D-Y (participants 12 to < 18 years of age). EQ-5D-5L descriptive system is comprised of 5 dimensions-mobility, self-care, usual activities, pain/discomfort & anxiety/depression. Each dimension has 5 levels: not at all (level 1), mild (level 2), moderate (level 3), severe (level 4), extreme/leading to incapacity (level 5), with highest level corresponding to worst outcome. Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states obtained for each dimension were then converted into a single median index value using the EQ-5D-5L crosswalk index value calculator as recommended by EuroQol group. In the EQ-VAS, participants recorded their health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). No data were collected or analyzed for this outcome measure due to early termination of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 up to 12 months

End point values	CMB305			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[9]			
Units: Score on a scale				

Notes:

[9] - The study terminated early and no endpoint data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants Who Discontinued Study Treatment Due to an AE

End point title	Number of Participants Who Discontinued Study Treatment Due to an AE
-----------------	--

End point description:

The number of all participants who discontinued study treatment due to an AE is presented. No data were collected or analyzed for this outcome measure due to early termination of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 2 months

End point values	CMB305			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[10]			
Units: Participants				

Notes:

[10] - The study terminated early and no endpoint data were analyzed.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

Up to approximately 2 months

Adverse event reporting additional description:

0 participants are reported due to the risk of identification of a person.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	n/a
--------------------	-----

Reporting groups

Reporting group title	CMB305
-----------------------	--------

Reporting group description:

Sequentially administered LV305 and G305.

Serious adverse events	CMB305		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	CMB305		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)		

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: The study terminated prior to data collection and analysis.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Study was stopped early due to Sponsor decision.
--

Notes: